Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Bernstein Reaffirms Their Hold Rating on Pfizer (PFE)
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The ...
Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering ...
BioSpace14h
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
FiercePharma14h
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
justthenews1d
Anti-white discrimination lawsuit against Pfizer reinstated after appeals court admits it goofed
Anti-woke medical group not required to unmask its members to challenge fellowship that excludes certain races, 2nd Circuit ...
Pfizer to sell 700M ordinary shares of Haleon
Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of ...
FiercePharma1d
JPM25, Day 1: Pfizer CEO discusses plan to overcome $17B 'LOE wave'
Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...